Analyzing the Causes of Cognitive Disorders Using PET Scans
Contribution of Brain Positon Emission Tomography With 18 Flurodeoxyglucose Labelled With Fluorine 18 for the Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
This study is testing if a special brain scan can help doctors figure out whether cognitive problems come from mental health issues or brain diseases in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Trial ID | NCT06463093 on ClinicalTrials.gov |
What this trial studies
This research aims to determine whether 18F-FDG PET imaging can assist in diagnosing the origins of cognitive disorders, distinguishing between psychiatric and neurodegenerative causes. Given the rising prevalence of neurocognitive disorders and their overlap with psychiatric conditions, this study seeks to clarify the underlying pathology to improve patient management. By analyzing adult patients with cognitive impairment who undergo PET scans, the study hopes to provide insights that could lead to better treatment strategies and improved patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients experiencing cognitive impairment who are undergoing PET imaging as part of their care.
Not a fit: Patients who object to the collection of their data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy and management of cognitive disorders, leading to improved patient care and quality of life.
How similar studies have performed: While the use of PET imaging in cognitive disorders is established, this specific approach to differentiate between psychiatric and neurodegenerative origins is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with cognitive impairment * Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care Exclusion Criteria: * Patients objecting to the collection of their data
Where this trial is running
Vandœuvre-lès-Nancy
- Nancy's hospital — Vandœuvre-lès-Nancy, France (Recruiting)
Study contacts
- Study coordinator: Antoine VERGER, MD, PhD
- Email: a.verger@chru-nancy.fr
- Phone: 0383153911
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.